Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.

In the phase 2b MIRACLE trial, adding the novel mineralocorticoid receptor modulator balcinrenone to dapagliflozin did not significantly reduce albuminuria compared with dapagliflozin alone in patients with heart failure and chronic kidney disease.